microRNA-21: a key modulator in oncogenic viral infections

References

• Plummer M, de Martel C, Vignat J, et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4(9):e609–616.
   PubMed Web of Science ®Google Scholar
• McBride AA. The promise of proteomics in the study of oncogenic viruses. Mol Cell Proteomics. 2017;16(4):S65–S74.
   PubMed Web of Science ®Google Scholar
• Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer. 2010;10:878–889.
   PubMed Web of Science ®Google Scholar
• Vojtechova Z, Tachezy R. The role of miRNAs in virus-mediated oncogenesis. Int J Mol Sci. 2018;19:1217.
   Web of Science ®Google Scholar
• Zhang T, Zhang J, You X, et al. Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells. Hepatology. 2012;56:2051–2059.
   PubMedGoogle Scholar
• Hsu CH, Peng KL, Jhang HC, et al. The HPV E6 oncoprotein targets histone methyltransferases for modulating specific gene transcription. Oncogene. 2012;31:2335–2349.
   PubMed Web of Science ®Google Scholar
• McClellan MJ, Khasnis S, Wood CD, et al. Downregulation of integrin receptor-signaling genes by Epstein-Barr virus EBNA 3C via promoter-proximal and -distal binding elements. J Virol. 2012;86:5165–5178.
   PubMed Web of Science ®Google Scholar
• Dall KL, Scarpini CG, Roberts I, et al. Characterization of naturally occurring HPV16 integration sites isolated from cervical keratinocytes under noncompetitive conditions. Cancer Res. 2008;68:8249–8259.
   PubMed Web of Science ®Google Scholar
• Bentwich I, Avniel A, Karov Y, et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet. 2005;37:766–770.
   PubMed Web of Science ®Google Scholar
• Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;9:102–114.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297.
   PubMed Web of Science ®Google Scholar
• Si ML, Zhu S, Wu H, et al. Mo, miR-21-mediated tumor growth. Oncogene. 2007;26:2799–2803.
   PubMed Web of Science ®Google Scholar
• Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA. J Cell Mol Med. 2009;13:39–53.
   PubMed Web of Science ®Google Scholar
• Choi B, Kim HA, Suh CH, et al. The relevance of miRNA-21 in HSV-induced inflammation in a mouse model. Int J Mol Sci. 2015;16:7413–7427.
   PubMed Web of Science ®Google Scholar
• Xu WD, Pan HF, Li JH, et al. MicroRNA-21 with therapeutic potential in autoimmune diseases. Expert Opin Ther Targets. 2013;17:659–665.
   PubMed Web of Science ®Google Scholar
• Wang S, Wan X, Ruan Q. The MicroRNA-21 in autoimmune diseases. Int J Mol Sci. 2016;17:864.
   Web of Science ®Google Scholar
• Fujita S, Ito T, Mizutani T, et al. miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. J Mol Biol. 2008;378:492–504.
   PubMed Web of Science ®Google Scholar
• Pan X, Wang ZX, Wang R. MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol Ther. 2010;10:1224–1232.
   PubMed Web of Science ®Google Scholar
• Feng YH, Tsao CJ. Emerging role of microRNA-21 in cancer. Biomed Rep. 2016;5:395–402.
   PubMed Web of Science ®Google Scholar
• Loffler D, Brocke-Heidrich K, Pfeifer G, et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood. 2007;110:1330–1333.
   PubMed Web of Science ®Google Scholar
• Huang Q, Zhang X, Bai F, et al. Methyl helicterte ameliorates liver fibrosis by regulating miR-21-mediated ERK and TGF-beta1/Smads pathways. Int Immunopharmacol. 2019;66:41–51.
   PubMed Web of Science ®Google Scholar
• Li CH, Xu F, Chow S, et al. Hepatitis B virus X protein promotes hepatocellular carcinoma transformation through interleukin-6 activation of microRNA-21 expression. Eur J Cancer. 2014;50:2560–2569.
   PubMed Web of Science ®Google Scholar
• Anastasiadou E, Garg N, Bigi R, et al. Epstein-Barr virus infection induces miR-21 in terminally differentiated malignant B cells. Int J Cancer. 2015;137:1491–1497.
   PubMed Web of Science ®Google Scholar
• Clerici M, Shearer GM. A TH1–>TH2 switch is a critical step in the etiology of HIV infection. Immunol today 1993;14:107–111.
   PubMedGoogle Scholar
• Lu TX, Hartner J, Lim EJ, et al. MicroRNA-21 limits in vivo immune response-mediated activation of the IL-12/IFN-gamma pathway, Th1 polarization, and the severity of delayed-type hypersensitivity. J Immunol. 2011;187:3362–3373.
   PubMed Web of Science ®Google Scholar
• Murugaiyan G, da Cunha AP, Ajay AK, et al. MicroRNA-21 promotes Th17 differentiation and mediates experimental autoimmune encephalomyelitis. J Clin Invest. 2015;125:1069–1080.
   PubMed Web of Science ®Google Scholar
• Al Akoum C, Akl I, Rouas R, et al. NFAT-1, Sp-1, Sp-3, and miR-21: new regulators of chemokine C receptor 7 expression in mature human dendritic cells. Hum Immunol. 2015;76:307–317.
   PubMed Web of Science ®Google Scholar
• Okamoto M, Matsuda H, Joetham A, et al. Jagged1 on dendritic cells and Notch on CD4+ T cells initiate lung allergic responsiveness by inducing IL-4 production. J Immunol. 2009;183:2995–3003.
   PubMed Web of Science ®Google Scholar
• Dong L, ang X, Tan J, et al. Decreased expression of microRNA-21 correlates with the imbalance of Th17 and Treg cells in patients with rheumatoid arthritis. J Cell Mol Med. 2014;18:2213–2224.
   PubMed Web of Science ®Google Scholar
• Smigielska-Czepiel K, van den Berg A, Jellema P, et al. Dual role of miR-21 in CD4+ T-cells: activation-induced miR-21 supports survival of memory T-cells and regulates CCR7 expression in naive T-cells. PLoS One. 2013;8:e76217.
   PubMedGoogle Scholar
• Rouas R, Fayyad-Kazan H, El Zein N, et al. Human natural Treg microRNA signature: role of microRNA-31 and microRNA-21 in FOXP3 expression. Eur J Immunol. 2009;39:1608–1618.
   PubMed Web of Science ®Google Scholar
• Bhairavabhotla R, Kim YC, Glass DD, et al. Transcriptome profiling of human FoxP3+ regulatory T cells. Hum Immunol. 2016;77:201–213.
   PubMed Web of Science ®Google Scholar
• Sheedy FJ, Palsson-McDermott E, Hennessy EJ, et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol. 2010;11:141–147.
   PubMed Web of Science ®Google Scholar
• Carissimi C, Carucci N, Colombo T, et al. miR-21 is a negative modulator of T-cell activation. Biochimie. 2014;107:319–326. Pt B
   PubMed Web of Science ®Google Scholar
• Wang L, He L, Zhang R, et al. Regulation of T lymphocyte activation by microRNA-21. Mol Immunol. 2014;59:163–171.
   PubMed Web of Science ®Google Scholar
• Naveed A, Ur-Rahman S, Abdullah S, et al. Review of MicroRNA exploring the insights of MicroRNA regulations in bacterial, viral and metabolic diseases. Mol Biotechnol. 2017;59:518–529.
   PubMed Web of Science ®Google Scholar
• Trobaugh DW, Klimstra WB. MicroRNA Regulation of RNA Virus Replication and Pathogenesis. Trends Mol Med. 2017;23:80–93.
   PubMed Web of Science ®Google Scholar
• Barbu MG, Condrat CE, Thompson DC, et al. MicroRNA involvement in signaling pathways during viral infection. Front Cell Dev Biol. 2020;8:143.
   PubMed Web of Science ®Google Scholar
• Kong Q, Wang W, Li P. Regulator role of HPV E7 protein on miR-21 expression in cervical carcinoma cells and its functional implication. Int J Clin Exp Pathol. 2015;8:8:15808–15813.
   Web of Science ®Google Scholar
• Xia B, Lu J, Wang R, et al. Huang, miR-21-3p regulates influenza A virus replication by targeting histone deacetylase-8. Front Cell Infect Microbiol. 2018;8:175.
   PubMed Web of Science ®Google Scholar
• Lupberger J, Hildt E. Hepatitis B virus-induced oncogenesis. World J Gastroenterol. 2007;13:74–81.
   PubMed Web of Science ®Google Scholar
• Qiu X, Dong S, Qiao F, et al. HBx-mediated miR-21 upregulation represses tumor-suppressor function of PDCD4 in hepatocellular carcinoma. Oncogene. 2013;32:3296–3305.
   PubMed Web of Science ®Google Scholar
• Bharali D, Banerjee BD, Bharadwaj M, et al. Expression analysis of MicroRNA-21 and MicroRNA-122 in hepatocellular carcinoma. J Clin Exp Hepatol. 2019;9:294–301.
   PubMed Web of Science ®Google Scholar
• Yin D, Wang Y, Sai W, et al. HBx-induced miR-21 suppresses cell apoptosis in hepatocellular carcinoma by targeting interleukin-12. Oncol Rep. 2016;36:2305–2312.
   PubMed Web of Science ®Google Scholar
• Dundar HZ, Aksoy F, Aksoy SA, et al. Overexpression of miR-21 is associated with recurrence in patients with hepatitis B virus-mediated hepatocellular carcinoma undergoing liver transplantation. Transplant Proc. 2019;51:1157–1161.
   PubMed Web of Science ®Google Scholar
• Houghton M, Weiner A, Han J, et al. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology. 1991;14:381–388.
   PubMed Web of Science ®Google Scholar
• Robertson B, Myers G, Howard C, et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. international committee on virus taxonomy. Arch Virol. 1998;143:2493–2503.
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Marrero JA, Rudolph L, et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752–1763.
   Web of Science ®Google Scholar
• Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41–52.
   PubMed Web of Science ®Google Scholar
• Wu J, Yang J, Ding J, et al. Exosomes in virus-associated cancer. Cancer Lett. 2018;438:44–51.
   PubMed Web of Science ®Google Scholar
• Tsuchiya N, Sawada Y, Endo I, et al. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2015;21:10573–10583.
   PubMed Web of Science ®Google Scholar
• Ghazy AA, Osman EM, Rashwan EA, et al. Relation between microRNA-21, transforming growth factor beta and response to treatment among chronic hepatitis C patients. J Med Virol. 2019;91:2166-2173.
   PubMed Web of Science ®Google Scholar
• Li Q, Zhang D, Wang Y, et al. MiR-21/Smad 7 signaling determines TGF-beta1-induced CAF formation. Sci Rep. 2013;3:2038.
   PubMed Web of Science ®Google Scholar
• Loboda A, Sobczak M, Jozkowicz A, et al. TGF-beta1/Smads and miR-21 in Renal Fibrosis and Inflammation. Mediators Inflamm. 2016;2016:8319283.
   PubMed Web of Science ®Google Scholar
• Clement S, Sobolewski C, Gomes D, et al. Activation of the oncogenic miR-21-5p promotes HCV replication and steatosis induced by the viral core 3a protein. Liver Int. 2019;39:1226–1236.
   PubMed Web of Science ®Google Scholar
• Li S, Zhu M, Pan R, et al. The tumor suppressor PTEN has a critical role in antiviral innate immunity. Nat Immunol. 2016;17:241–249.
   PubMed Web of Science ®Google Scholar
• Cao LQ, Yang XW, Chen YB, et al. Exosomal miR-21 regulates the TETs/PTENp1/PTEN pathway to promote hepatocellular carcinoma growth. Mol Cancer. 2019;18:148.
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783–801.
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen J, Wang H, et al. HCV-induced miR-21 contributes to evasion of host immune system by targeting MyD88 and IRAK1. PLoS Pathog. 2013;9:e1003248.
   PubMed Web of Science ®Google Scholar
• Crosbie EJ, Kitchener HC. Human papillomavirus in cervical screening and vaccination. Clin Sci (Lond). 2006;110:543–552.
   PubMed Web of Science ®Google Scholar
• McGuire S, Report WC. Geneva, Switzerland: world health organization, international agency for research on cancer, WHO press, 2015. Adv Nutr. 2014;7(2016):418–419.
   Google Scholar
• Peralta-Zaragoza O, Deas J, Meneses-Acosta A, et al. Relevance of miR-21 in regulation of tumor suppressor gene PTEN in human cervical cancer cells. BMC Cancer. 2016;16:215.
   PubMed Web of Science ®Google Scholar
• Bumrungthai S, Ekalaksananan T, Evans MF, et al. Up-Regulation of miR-21 is associated with cervicitis and human papillomavirus infection in cervical tissues. PLoS One. 2015;10:e0127109.
   PubMed Web of Science ®Google Scholar
• Shishodia G, Shukla S, Srivastava Y, et al. Alterations in microRNAs miR-21 and let-7a correlate with aberrant STAT3 signaling and downstream effects during cervical carcinogenesis. Mol Cancer. 2015;14:116.
   PubMed Web of Science ®Google Scholar
• Jiang S, Dong Y. Human papillomavirus and oral squamous cell carcinoma: a review of HPV-positive oral squamous cell carcinoma and possible strategies for future. Curr Probl Cancer. 2017;41:323–327.
   PubMed Web of Science ®Google Scholar
• Honegger A, Schilling D, Bastian S, et al. Dependence of intracellular and exosomal microRNAs on viral E6/E7 oncogene expression in HPV-positive tumor cells. PLoS Pathog. 2015;11:e1004712.
   PubMed Web of Science ®Google Scholar
• Rogers L, Siu SS, Luesley D, et al. Radiotherapy and chemoradiation after surgery for early cervical cancer. Cochrane Database Syst Rev. 2012;5:CD007583.
   PubMed Web of Science ®Google Scholar
• Waggoner SE. Cervical cancer. Lancet. 2003;361:2217–2225.
   PubMed Web of Science ®Google Scholar
• Powell ME. Modern radiotherapy and cervical cancer. Int J Gynecol Cancer. 2010;20:S49–51.
   PubMed Web of Science ®Google Scholar
• Liu S, Song L, Zhang L, et al. miR-21 modulates resistance of HR-HPV positive cervical cancer cells to radiation through targeting LATS1. Biochem Biophys Res Commun. 2015;459:679–685.
   PubMed Web of Science ®Google Scholar
• Zuo L, Yue W, Du S, et al. An update: epstein-Barr virus and immune evasion via microRNA regulation. Virol Sin. 2017;32:175–187.
   PubMed Web of Science ®Google Scholar
• Okuno Y, Murata T, Sato Y, et al. Defective Epstein-Barr virus in chronic active infection and haematological malignancy. Nat Microbiol. 2019;4:404–413.
   PubMed Web of Science ®Google Scholar
• Albanese M, Tagawa T, Bouvet M, et al. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells. Proc Natl Acad Sci U S A. 2016;113:E6467–E6475.
   PubMed Web of Science ®Google Scholar
• Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005;365:2041–2054.
   PubMed Web of Science ®Google Scholar
• Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer. 2011;30:114–119.
   PubMedGoogle Scholar
• Langendijk JA, Leemans CR, Buter J, et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol. 2004;22:4604–4612.
   PubMed Web of Science ®Google Scholar
• Yang GD, Huang TJ, Peng LX, et al. Epstein-Barr Virus_Encoded LMP1 upregulates microRNA-21 to promote the resistance of nasopharyngeal carcinoma cells to cisplatin-induced Apoptosis by suppressing PDCD4 and Fas-L. PLoS One. 2013;8:e78355.
   PubMed Web of Science ®Google Scholar
• Xin L, Yang WF, Zhang HT, et al. The mechanism study of lentiviral vector carrying methioninase enhances the sensitivity of drug-resistant gastric cancer cells to Cisplatin. Br J Cancer. 2018;118:1189–1199.
   PubMed Web of Science ®Google Scholar
• Stevenson M. HIV-1 pathogenesis. Nat Med. 2003;9:853–860.
   PubMed Web of Science ®Google Scholar
• Ruiz-de-Leon MJ, Jimenez-Sousa MA, Moreno S, et al. E.N.i.i.t.S.A.R. Network, Lower expression of plasma-derived exosome miR-21 levels in HIV-1 elite controllers with decreasing CD4 T cell count. J Microbiol Immunol Infect. 2019;52:667–671.
   PubMedGoogle Scholar
• Bannwarth S, Gatignol A. HIV-1 TAR RNA: the target of molecular interactions between the virus and its host. Curr HIV Res. 2005;3:61–71.
   PubMed Web of Science ®Google Scholar
• Gatignol A, Jeang KT. Tat as a transcriptional activator and a potential therapeutic target for HIV-1. Adv Pharmacol. 2000;48:209–227.
   PubMedGoogle Scholar
• Sanchez-Del Cojo M, Lopez-Huertas MR, Diez-Fuertes F, et al. Changes in the cellular microRNA profile by the intracellular expression of HIV-1 Tat regulator: a potential mechanism for resistance to apoptosis and impaired proliferation in HIV-1 infected CD4+ T cells. PLoS One. 2017;12:e0185677.
   PubMed Web of Science ®Google Scholar
• Jiao Y, Zhang T, Wang R, et al. 10 is associated with rapid disease progression in early HIV-1 infection. Viral Immunol. 2012;25:333–337.
   PubMed Web of Science ®Google Scholar
• Wu X, Zhang LL, Yin LB, et al. Deregulated MicroRNA-21 Expression in monocytes from HIV-infected patients contributes to elevated IP-10 secretion in HIV infection. Front Immunol. 2017;8:1122.
   PubMed Web of Science ®Google Scholar
• Simmons RP, Scully EP, Groden EE, et al. HIV-1 infection induces strong production of IP-10 through TLR7/9-dependent pathways. AIDS. 2013;27:2505–2517.
   PubMed Web of Science ®Google Scholar
• Ramirez LA, Arango TA, Thompson E, et al. 10 levels decrease T cell function in HIV-1-infected individuals on ART. J Leukoc Biol. 2014;96:1055–1063.
   PubMed Web of Science ®Google Scholar
• Lane BR, King SR, Bock PJ, et al. The C-X-C chemokine IP-10 stimulates HIV-1 replication. Virology. 2003;307:122–134.
   PubMed Web of Science ®Google Scholar
• Yelamanchili SV, Chaudhuri AD, Chen LN, et al. MicroRNA-21 dysregulates the expression of MEF2C in neurons in monkey and human SIV/HIV neurological disease. Cell Death Dis. 2010;1:e77.
   PubMed Web of Science ®Google Scholar
• Yelamanchili SV, Lamberty BG, Rennard DA, et al. MiR-21 in extracellular vesicles leads to neurotoxicity via TLR7 signaling in SIV neurological disease. PLoS Pathog. 2015;11:e1005032.
   PubMed Web of Science ®Google Scholar
• Le Meur N, Holder-Espinasse M, Jaillard S, et al. MEF2C haploinsufficiency caused by either microdeletion of the 5q14.3 region or mutation is responsible for severe mental retardation with stereotypic movements, epilepsy and/or cerebral malformations. J Med Genet. 2010;47:22–29.
   PubMed Web of Science ®Google Scholar
• Garaci E, Aquaro S, Lapenta C, et al. Anti-nerve growth factor Ab abrogates macrophage-mediated HIV-1 infection and depletion of CD4+ T lymphocytes in hu-SCID mice. Proc Natl Acad Sci U S A. 2003;100:8927–8932.
   PubMed Web of Science ®Google Scholar
• Feng N, Zhou Z, Li Y, et al. Enterovirus 71-induced has-miR-21 contributes to evasion of host immune system by targeting MyD88 and IRAK1. Virus Res. 2017;237:27–36.
   PubMed Web of Science ®Google Scholar
• Kanokudom S, Vilaivan T, Wikan N, et al. miR-21 promotes dengue virus serotype 2 replication in HepG2 cells. Antiviral Res. 2017;142:169–177.
   PubMed Web of Science ®Google Scholar
• Li Y, Wu R, Liu Z, et al. Enforced expression of microRNA-21 influences the replication of varicella-zoster virus by triggering signal transducer and activator of transcription 3. Exp Ther Med. 2014;7:1291–1296.
   PubMed Web of Science ®Google Scholar
• Huang J, Ma G, Fu L, et al. Pseudorabies viral replication is inhibited by a novel target of miR-21. Virology. 2014;456-457:319–328.
   PubMed Web of Science ®Google Scholar
• Wang YS, Ouyang W, Pan QX, et al. Overexpression of microRNA gga-miR-21 in chicken fibroblasts suppresses replication of infectious bursal disease virus through inhibiting VP1 translation. Antiviral Res. 2013;100:196–201.
   PubMed Web of Science ®Google Scholar
• Yang T, Xing H, Wang G, et al. A novel online calculator based on serum biomarkers to detect hepatocellular carcinoma among patients with hepatitis B. Clin Chem. 2019;65:1543-1553.
   Web of Science ®Google Scholar
• Park S, Eom K, Kim J, et al. MiR-9, miR-21, and miR-155 as potential biomarkers for HPV positive and negative cervical cancer. BMC Cancer. 2017;17:658.
   PubMed Web of Science ®Google Scholar
• Zamani S, Sohrabi A, Hosseini SM, et al. Deregulation of miR-21 and miR-29a in Cervical Cancer Related to HPV Infection. Microrna. 2019;8:110–115.
   PubMedGoogle Scholar
• Waring BM, Sjaastad LE, Fiege JK, et al. MicroRNA-based attenuation of influenza virus across susceptible hosts. J Virol. 2018;92:e01741-17
   Web of Science ®Google Scholar
• Marzulli M, Mazzacurati L, Zhang M, et al. Herpes simplex virus design based on the common overexpression of microRNA-21 in Tumors.
   Google Scholar
• Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30:658–670.
   PubMed Web of Science ®Google Scholar
• Fu LQ, Wang SB, Cai MH, et al. Recent advances in oncolytic virus-based cancer therapy. Virus Res. 2019;270:197675.
   PubMed Web of Science ®Google Scholar
• Campadelli-Fiume G, De Giovanni C, Gatta V, et al. Rethinking herpes simplex virus: the way to oncolytic agents. Rev Med Virol. 2011;21:213–226.
   PubMed Web of Science ®Google Scholar
• Lee CY, Rennie PS, Jia WW. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells. Clin Cancer Res. 2009;15:5126–5135.
   PubMed Web of Science ®Google Scholar
• Mazzacurati L, Marzulli M, Reinhart B, et al. Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV. Mol Ther. 2015;23:99–107.
   PubMed Web of Science ®Google Scholar